Table 1.

Patient characteristics at baseline.

TNFi Monotherapy, n = 320TNFi + SSZ, n = 103TNFi + LEF, n = 80TNFi + Other csDMARD, n = 99TNFi + MTX, n = 919TNFi + MTX + csDMARD, n = 412p*
Female (%)74.476.770.069.768.663.10.015
Mean age, yrs (SD)56.7 (13.0)56.4 (15.2)55.2 (12.1)57.1 (13.2)55.0 (13.0)54.7 (12.8)0.167
Median disease duration, yrs (IQR)8.01 (2.35–15.4)5.85 (2.10–11.97)6.67 (2.08–11.97)4.83 (1.78–12.22)4.90 (1.82–11.63)4.04 (1.11–9.17)< 0.001
Mean DAS28 (SD)5.23 (1.32)5.02 (1.32)4.91 (1.29)4.77 (1.40)4.89 (1.34)4.79 (1.26)0.001
Mean HAQ-DI (SD)1.48 (0.64)1.41 (0.66)1.35 (0.67)1.49 (1.09)1.30 (0.69)1.27 (0.64)< 0.001
RF positivity (%)67.071.877.970.270.765.20.163
Erosive disease (%)68.459.457.463.866.153.10.003
No. previous DMARD (%)< 0.001
17.83.91.26.111.41.5
225.638.816.221.248.459.2
323.435.033.824.226.024.8
421.615.526.220.29.19.2
> 421.66.822.528.35.05.3
TNFi (%)< 0.001
ADA33.442.737.535.444.635.6
ETN57.450.546.248.541.757.3
IFX9.16.816.216.213.77.2
  • * p value was the result of ANOVA, Kruskal-Wallis, and chi-squared analyses.

  • No. csDMARD tried before the start of TNFi treatment. DAS28: Disease Activity Score of 28 joints; HAQ-DI: Health Assessment Questionnaire–Disability Index; IQR: interquartile range; csDMARD: conventional synthetic disease-modifying antirheumatic drug; MTX: methotrexate; TNFi: tumor necrosis factor inhibitor; SSZ: sulfasalazine; LEF: leflunomide; RF: rheumatoid factor.